Compare DexCom, Inc. (DXCM) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Royal Caribbean Cruises Ltd — how do they compare? DexCom, Inc. trades at $90.64 (market cap $33.79B), while Royal Caribbean Cruises Ltd trades at $308 (market cap $82.15B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 2.4× DexCom, Inc.'s market cap, and Royal Caribbean Cruises Ltd pays a 1.63% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | RCL | |
|---|---|---|
Market Cap | $33.79B | $82.15B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $365.84 |
52-Week Low | $54.84 | $246.71 |
Enterprise Value | $33.24B | $104.79B |
Dividend Yield | — | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
Royal Caribbean (RCL) trades at $307.87, showing minimal daily movement (-0.04%) with a bullish technical signal. The company demonstrates strong fundamental momentum with Q2 2026 EPS beating expectations at $4.21 versus $3.98, and robust profitability metrics including 23.54% net income margin and 45.33% ROE. Recent news highlights strong demand trends and the pricing of $1.25 billion in senior notes to support growth initiatives.
RCL presents a compelling growth story with record bookings and improved financial health, though elevated valuation ratios (P/E 18.97, P/S 4.46) and geopolitical risks in Europe warrant caution. Analyst consensus remains positive with a $343.09 price target, suggesting approximately 11% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
